S-27	Sie reichen nicht aus, um Dosierungsvorschläge zu machen, und daher wird eine Anwendung in dieser Altersgruppe nicht empfohlen.
T-27	These are insufficient to make dosage recommendations and therefore use in this age group is not recommended.
R0: recommendations dosage insufficient
base-27	57.37	0.33	They are not sufficient to suggest dosage, and therefore use in this age group is not recommended.
knn-27	39.67	0.00	They are not sufficient to suggest dosages, and therefore an application in this age group is not recommended.

S-44	Bei nierentransplantierten Patienten mit schweren Leberparenchymschäden sind Dosisanpassungen nicht erforderlich.
T-44	No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease.
R0: disease parenchymal
base-44	66.06	0.50	No dose adjustments are needed in renal transplant patients with severe hepatic parenchymal damage.
knn-44	0.00	0.00	Dose adjustments are not necessary in kidney transplanted patients with severe liver parenchyma damage.

S-50	Pharmakokinetische Daten bei Lebertransplantatabstoßung liegen nicht vor.
T-50	No pharmacokinetic data are available during hepatic transplant rejection.
R0: pharmacokinetic
base-50	31.24	1.00	There is no pharmacokinetic data in hepatic transplant rejection.
knn-50	0.00	0.00	Pharmacokinetic data for liver transplant rejection are not available.

S-58	Patienten, die mit Myfenax behandelt werden, sollen angewiesen werden, sofort über jedes Anzeichen einer Infektion, unerwartete Blutergüsse, Blutungen oder andere Manifestationen einer Suppression des Knochenmarks zu berichten.
T-58	Patients receiving Myfenax should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression.
R0: bruising depression marrow bone instructed unexpected manifestation evidence infection bleeding report
base-58	73.23	0.82	Patients receiving Myfenax should be instructed to immediately report any signs of infection, unexpected bruising, bleeding or any other manifestation of bone marrow suppression.
knn-58	46.69	0.73	Patients treated with Myfenax should be instructed to immediately report any signs of infection, unexpected bruising, bleeding or other manifestations of bone marrow suppression.

S-61	Diese Infektionen sind häufig mit einer hohen immunsuppressiven Gesamtexposition verbunden und können zu einer schwerwiegenden oder tödlichen Erkrankung führen, die Ärzte bei immunsupprimierten Patienten mit sich verschlechternder Nierenfunktion oder neurologischen Symptomen differentialdiagnostisch in Betracht ziehen müssen.
T-61	These infections are often related to a high total immunosuppressive burden and may lead to serious or fatal conditions that physicians should consider in the differential diagnosis in immunosuppressed patients with deteriorating renal function or neurological symptoms.
R0: neurological burden physicians immunosuppressed total differential deteriorating diagnosis symptoms conditions
base-61	26.24	0.40	These infections are often associated with a high overall immunosuppressive exposure and can lead to a serious or fatal disease that physicians must consider in immunosuppressive patients with deteriorating kidney function or neurological symptoms.
knn-61	24.14	0.30	These infections are often associated with high overall immunosuppressive exposure and can lead to a serious or fatal disease that physicians must consider in immunosuppressive patients with worsening kidney function or neurological symptoms.

S-64	Wenn sich eine Neutropenie entwickelt (absolute Neutrophilen-Zahl < 1,3 x 103 / µl), könnte es angebracht sein, die Behandlung mit Myfenax abzubrechen oder zu unterbrechen.
T-64	If neutropenia develops (absolute neutrophil count < 1.3 x 103 / μ l) it may be appropriate to interrupt or discontinue Myfenax.
R0: count develops interrupt absolute neutrophil discontinue μ
base-64	48.60	0.71	If neutropenia develops (absolute neutrophil rate < 1.3 x 103 / µL), it may be appropriate to discontinue or interrupt Myfenax treatment.
knn-64	45.31	0.43	If neutropenia develops (absolute neutropenia < 1.3 x 103 / µl), it may be appropriate to discontinue or discontinue treatment with Myfenax.

S-73	Das Nutzen-Risiko-Verhältnis von Mycophenolatmofetil in Kombination mit Tacrolimus wurde noch nicht untersucht (siehe auch Abschnitt 4.5).
T-73	The risk-benefit ratio of mycophenolate mofetil in combination with tacrolimus or sirolimus has not been established (see also section 4.5).
R0: tacrolimus ratio risk-benefit established sirolimus
base-73	58.66	0.60	The risk-benefit ratio of mycophenolate mofetil in combination with tacrolimus has not been studied (see section 4.5).
knn-73	45.01	0.40	The benefit-risk ratio of mycophenolate mofetil in combination with tacrolimus has not yet been investigated (see also Section 4.5).

S-76	Aciclovir: Im Vergleich zur alleinigen Gabe von Aciclovir, wurden höhere Plasmakonzentrationen von Aciclovir beobachtet, wenn Mycophenolatmofetil und Aciclovir zusammen verabreicht wurden.
T-76	Aciclovir: higher aciclovir plasma concentrations were observed when mycophenolate mofetil was administered with aciclovir in comparison to the administration of aciclovir alone.
R0: plasma concentrations aciclovir Aciclovir comparison
base-76	33.07	1.00	Aciclovir: In comparison with the administration of aciclovir alone, higher plasma concentrations of aciclovir were observed when mycophenolate mofetil and aciclovir were administered concomitantly.
knn-76	24.18	0.80	Aciclovir: Compared to aciclovir alone, higher plasma concentrations of aciclovir were observed when mycophenolate mofetil and aciclovir were administered together.

S-83	Ciclosporin A: Die Pharmakokinetik von Ciclosporin A (CsA) wurde durch Mycophenolatmofetil nicht beeinflusst.
T-83	Ciclosporin A: ciclosporin A (CsA) pharmacokinetics were unaffected by mycophenolate mofetil.
R0: unaffected Ciclosporin CsA
base-83	41.92	0.67	Ciclosporin A: The pharmacokinetics of ciclosporin A (CsA) were not influenced by mycophenolate mofetil.
knn-83	30.93	0.33	Ciclosporine A: The pharmacokinetics of ciclosporine A (CsA) were not influenced by mycophenolate mofetil.

S-122	Die häufigsten Nebenwirkungen im Zusammenhang mit der Verabreichung von Mycophenolat in Kombination mit Ciclosporin und Corticosteroiden sind Diarrhö, Leukopenie, Sepsis und Erbrechen, und es ist erwiesen, dass bestimmte Infektionsarten häufiger auftreten (siehe Abschnitt 4.4).
T-122	The principal adverse reactions associated with the administration of mycophenolate in combination with ciclosporin and corticosteroids include diarrhoea, leucopenia, sepsis and vomiting and there is evidence of a higher frequency of certain types of infections (see section 4.4).
R0: principal vomiting types diarrhoea leucopenia include
base-122	39.93	0.50	The most common adverse reactions to mycophenolate in combination with ciclosporin and corticosteroids are diarrhoea, leukopenia, sepsis and vomiting and certain types of infections have been shown to be more common (see section 4.4).
knn-122	38.88	0.33	The most common adverse events associated with the administration of mycophenolate in combination with ciclosporine and corticosteroids are diarrhea, leukopenia, sepsis and vomiting, and certain types of infection have been shown to be more common (see section 4.4).

S-177	501 (Tagesdosis: 2 g Mycophenolat), 289 (Tagesdosis: 3 g Mycophenolat) und 277 (Tagesdosis: 2 g intravenös / 3 g Mycophenolat oral) Patienten wurden in Phase-III-Studien zur Verhinderung einer Abstoßung nach Nieren-, Herz- und Lebertransplantation behandelt.
T-177	501 (2 g mycophenolate daily), 289 (3 g mycophenolate daily) and 277 (2 g intravenous / 3 g oral mycophenolate daily) patients were treated in Phase III studies for the prevention of rejection in renal, cardiac and hepatic transplantation, respectively.
R0: Phase prevention III
base-177	30.37	0.67	501 (daily dose: 2 g of mycophenolate), 289 (daily dose: 3 g of mycophenolate) and / or 277 (daily dose: 2 g of intravenous / 3 g of mycophenolate orally) patients were treated in Phase III trials to prevent rejection following renal, cardiac and hepatic transplants.
knn-177	27.77	0.33	501 (daily dose: 2 g mycophenolate), 289 (daily dose: 3 g mycophenolate) and 277 (daily dose: 2 g intravenously / 3 g mycophenolate orally) patients were treated in Phase II studies to prevent rejection after kidney, heart and liver transplantation.

S-207	In klinisch relevanten Konzentrationen ist Mycophenolsäure zu 97% an Plasmaalbumin gebunden.
T-207	MPA at clinically relevant concentrations, is 97% bound to plasma albumin.
R0: bound albumin
base-207	64.75	1.00	In clinically relevant concentrations, mycophenolic acid is 97% bound to plasma albumin.
knn-207	23.51	0.50	In clinically relevant concentrations, 97% of mycophenolic acid is bound to plasmaalbumin.

S-253	Das Blut bildende System und das Lymphsystem waren die Organe, die in den toxikologischen Studien mit Mycophenolatmofetil bei Ratten, Mäusen, Hunden und Affen in erster Linie betroffen waren.
T-253	The haematopoietic and lymphoid systems were the primary organs affected in toxicology studies conducted with mycophenolate mofetil in the rat, mouse, dog and monkey.
R0: lymphoid rat organs haematopoietic dog toxicology systems monkey
base-253	0.00	0.25	The blood-forming system and lymphatic system were the organs primarily affected in the toxicology studies of mycophenolate mofetil in rats, mice, dogs and monkeys.
knn-253	0.00	0.12	The blood-forming system and the lymphatic system were the organs primarily affected in toxicological studies of mycophenolate mofetil in rats, mice, dogs and monkeys.

S-273	Transparente PVC / PVdC-Aluminium-Blisterpackungen in Packungsgrößen zu 100 oder 300 Kapseln pro Faltschachtel.
T-273	Transparent PVC / PVdC - aluminium blisters in pack sizes of 100 or 300 capsules per carton.
R0: PVC blisters pack sizes carton PVdC Transparent
base-273	54.02	0.86	Transparent PVC / PVdC aluminium blister packs in pack sizes of 100 or 300 capsules / folding carton.
knn-273	56.33	0.71	Transparent PVC / PVdCaluminium blister packs in pack sizes of 100 or 300 capsules per folding carton.

S-466	Die Einnahme von Nahrungsmitteln und Getränken hat keinen Einfluss auf Ihre Behandlung mit Myfenax.
T-466	Taking Myfenax with food and drink Taking food and drink has no influence on your treatment with Myfenax.
R0: drink
base-466	43.68	1.00	The intake of food and drink has no effect on your treatment with Myfenax.
knn-466	21.39	0.00	The intake of food and beverages does not affect your treatment with Myfenax.

S-509	Sehr häufige Nebenwirkungen betreffen wahrscheinlich mehr als 1 von 10 Patienten: • Durchfall, Erbrechen, Übelkeit • Eine Verminderung der Normalwerte von verschiedenen Blutkörperchen, was zu einem erhöhten Risiko für Infektionen, Blutergüsse, Blutungen, Atemlosigkeit und Schwäche führen kann
T-509	Very common side effects likely to affect more than 1 in 10 people: • Diarrhoea, vomiting, feeling sick • Decrease in normal amounts of different blood cells, which can result in increased risk of infections, bruising, bleeding, breathlessness and weakness • Bacterial, fungal and viral infections of the digestive and urinary tract, cold sores and shingles
R0: Diarrhoea cold sores breathlessness people feeling Bacterial weakness shingles Decrease sick affect
base-509	27.94	0.33	Very common adverse reactions probably affect more than 1 in 10 patients: • Diarrhoea, vomiting, nausea • decrease in the normal levels of various blood cells, which may increase the chance of infection, bruising, bleeding, breathlessness and weakness
knn-509	27.83	0.25	Very common adverse events probably affect more than 1 in 10 patients: • Diarrhea, vomiting, nausea • A reduction in the normal levels of various blood cells, which can lead to an increased risk of infection, bruising, bleeding, breathlessness and weakness

S-19	Olanzapin ist zur Behandlung von mäßig schweren bis schweren manischen Episoden angezeigt.
T-19	Olanzapine is indicated for the treatment of moderate to severe manic episode.
R0: manic severe moderate episode
base-19	84.24	0.75	Olanzapine is indicated for the treatment of moderate to severe manic episodes.
knn-19	54.45	0.50	Olanzapine is indicated for the treatment of moderately severe to severe manic episodes.

S-30	Während der Behandlung einer Schizophrenie, einer manischen Episode und zur Phasenprophylaxe bei bipolaren Störungen kann die Dosis anschließend innerhalb eines Bereichs von 5-20 mg / Tag auf der Grundlage des individuellen klinischen Zustands angepaßt werden.
T-30	During treatment for schizophrenia, manic episode and recurrence prevention in bipolar disorder, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5-20 mg / day.
R0: range subsequently basis dosage 5-20 status adjusted individual
base-30	34.16	0.62	During the treatment of schizophrenia, manic episode or phase prophylaxis in bipolar disorder, the dose can be adjusted within a range of 5-20 mg / day on the basis of the individual clinical condition.
knn-30	30.39	0.50	During the treatment of schizophrenia, manic episode and phase prophylaxis of bipolar disorder, the dose can then be adjusted within a range of 5-20 mg / day based on the individual clinical condition.

S-46	In Fällen von mittelgradiger Leberinsuffizienz (Zirrrhose, Child-Pugh Klasse A oder B) sollte die Anfangsdosis 5 mg betragen und nur mit Vorsicht erhöht werden.
T-46	In cases of moderate hepatic insufficiency (cirrhosis, Child-Pugh Class A or B), the starting dose should be 5 mg and only increased with caution.
R0: Class increased insufficiency Child-Pugh caution cirrhosis
base-46	66.10	0.67	In cases of moderate hepatic impairment (cirrhosis, Child- Pugh Class A or B), the starting dose should be 5 mg and should be increased with caution.
knn-46	46.16	0.50	In cases of moderate liver failure (cirrhosis, Child- Pugh class A or B) the starting dose should be 5 mg and should be increased only with caution.

S-151	Erwachsene Die am häufigsten (1% der Patienten) berichteten Nebenwirkungen im Zusammenhang mit der Anwendung von Olanzapin in klinischen Prüfungen waren Schläfrigkeit, Gewichtszunahme, Eosinophilie, erhöhte Prolaktin-, Cholesterin-, Glukose- und Triglyceridspiegel (siehe Abschnitt 4.4).
T-151	Adults The most frequently (seen in 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects,
R0: triglyceride eosinophilia glucosuria appetite parkinsonism orthostatic akathisia cholesterol
base-151	43.47	0.38	Adults The most reported adverse reactions associated with the use of olanzapine in clinical trials (1% of patients) were sleepiness, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4).
knn-151	24.51	0.25	Adults The most commonly reported adverse events (1% of patients) associated with olanzapine use in clinical trials were drowsiness, weight gain, eosinophilia, elevated levels of prolactin, cholesterol, glucose and triglycerides (see Section 4.4).

S-163	Thrombozytopenie
T-163	Thrombocytopenia
R0: Thrombocytopenia
base-163	100.00	1.00	Thrombocytopenia
knn-163	0.00	0.00	thrombocytopenia

S-164	Erkrankungen des Immunsytems Allergische Reaktion Stoffwechsel- und Ernährungsstörungen Gewichtszunahme1
T-164	Immune system disorders Allergic reaction Metabolism and nutrition disorders Weight gain1
R0: nutrition Allergic reaction Metabolism Immune Weight gain1
base-164	21.97	0.57	Diseases of the immune system Allergic reaction Metabolic and nutrition disorders Weight gain 1
knn-164	0.00	0.43	Diseases of the immune system Allergic reaction Metabolic and nutritional disorders Weight gain 1

S-185	Hohe Kreatin- Phosphokinase Werte Erhöhtes Gesamtbilirubin
T-185	High creatine phosphokinase Increased total bilirubin
R0: creatine total bilirubin
base-185	0.00	0.67	High creatinine phosphokinase levels Elevated total bilirubin
knn-185	0.00	0.33	High Creatine Phosphokinase Values Increased Total bilirubin

S-191	3 Beobachtet wurden normale Nüchtern-Ausgangswerte (< 5,17mmol / l), die über die Normwerte anstiegen (6,2mmol / l).
T-191	3 Observed for fasting normal levels at baseline (< 5.17 mmol / l) which increased to high (6.2 mmol / l).
R0: Observed normal mmol
base-191	17.58	0.33	3 Normal fasting baseline values (< 5.17 mmo1 / l) were observed, which were higher than the normal values (6.2 mmo1 / l).
knn-191	16.28	0.00	3 Normal fasting baseline values (< 5.17mmol / l) were observed, which rose above the norm values (6.2mmol / l).

S-222	Gewichtszunahme9, erhöhte Triglyceridspiegel10, Zunahme des Appetits.
T-222	Weight gain9, elevated triglyceride levels10, increased appetite.
R0: gain9 levels10
base-222	41.72	0.50	Weight gain9, elevated triglyceride level10, increase in appetite.
knn-222	0.00	0.00	Weight gain 9, increased triglyceride level10, increase in appetite.

S-230	Erniedrigtes Gesamtbilirubin, erhöhte GGT, erhöhte Plasmaprolaktinspiegel12.
T-230	Decreased total bilirubin, increased GGT, elevated plasma prolactin levels12.
R0: GGT levels12
base-230	73.49	1.00	Decreased total bilirubin, increased GGT, increased plasma prolactin levels12.
knn-230	48.33	0.50	Reduced total bilirubin, increased GGT, increased plasma prolactin level12.

S-302	Die Plasmaproteinbindung von Olanzapin betrug etwa 93% über einen Konzentrationsbereich von etwa 7 bis etwa 1.000 ng / ml.
T-302	The plasma protein binding of olanzapine was about 93% over the concentration range of about 7 to about 1000 ng / ml.
R0: protein binding concentration
base-302	76.41	1.00	The plasma protein binding of olanzapine was about 93% over a concentration range of about 7 to about 1,000 ng / ml.
knn-302	63.62	0.67	The plasma protein integration of olanzapine was about 93% over a concentration range of about 7 to about 1,000 ng / ml.

S-615	WELCHE NEBENWIRKUNGEN SIND MÖGLICH?
T-615	POSSIBLE SIDE EFFECTS
R0: EFFECTS
base-615	0.00	1.00	WHAT EFFECTS ARE POSSIBLE?
knn-615	0.00	0.00	WHAT IMPACT ARE POSSIBLE?

S-41	Wenn Zusatzmedikation mit oralem Olanzapin klinisch angezeigt ist, darf die addierte Gesamtdosis der beiden Darreichungsformen die maximal zugelassene Dosis für orales Olanzapin von 20 mg / Tag nicht überschreiten.
T-41	If oral olanzapine supplementation is clinically indicated, then the combined total dose of olanzapine from both formulations should not exceed the corresponding maximum oral olanzapine dose of 20 mg / day.
R0: total formulations supplementation maximum exceed combined clinically
base-41	30.07	0.71	If supplementation with oral olanzapine is clinically indicated, the total added dose of the two dosage forms must not exceed the maximum authorised dose for oral olanzapine of 20 mg / day.
knn-41	29.17	0.57	If additional medication with oral olanzapine is clinically indicated, the total added dose of both forms of administration must not exceed the maximum permitted dose for oral olanzapine of 20 mg / day.

S-50	In Fällen mit einer mittelgradigen Leberinsuffizienz (Zirrhose, Child-Pugh Klasse A oder B), sollte die Anfangsdosis 150 mg / 4 Wochen betragen und nur mit Vorsicht erhöht werden.
T-50	In cases of moderate hepatic insufficiency (cirrhosis, Child- Pugh Class A or B), the starting dose should be 150 mg every 4 weeks and only increased with caution.
R0: Class increased Child- insufficiency caution moderate cirrhosis Pugh
base-50	71.96	1.00	In cases with moderate hepatic insufficiency (cirrhosis, Child- Pugh Class A or B), the starting dose should be 150 mg / 4 weeks and should only be increased with caution.
knn-50	60.85	0.88	In cases with moderate liver failure (cirrhosis, Child- Pugh Class A or B), the starting dose should be 150 mg / 4 weeks and should be increased only with caution.

S-89	Als Risikofaktoren für ein zerebrovaskuläres Ereignis im Zusammenhang mit einer Olanzapin-Behandlung wurden ein Alter > 75 Jahre und eine Demenz vaskulärer oder gemischter Ursache identifiziert.
T-89	Age > 75 years and vascular / mixed type dementia were identified as risk factors for CVAE in association with olanzapine treatment.
R0: Age dementia mixed identified association vascular type
base-89	20.26	0.57	Risk factors for a cerebrovascular event associated with olanzapine treatment were identified as age > 75 years and dementia of vascular or mixed cause.
knn-89	0.00	0.43	Risk factors for a cerebrovascular event associated with olanzapine treatment were identified as > 75 years of age and vascular or mixed-cause dementia.

S-103	Patienten, die mit antipsychotischen Arzneimitteln einschließlich ZYPADHERA behandelt werden, sollten hinsichtlich Symptomen einer Hyperglykämie (wie Polydipsie, Polyurie, Polyphagie und Schwäche) beobachtet werden. Patienten mit Diabetes mellitus oder mit Risikofaktoren für die Entwicklung eines Diabetes sollten regelmäßig bezüglich einer Verschlechterung der Glukoseeinstellung überwacht werden.
T-103	Patients treated with any antipsychotic agents, including ZYPADHERA, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control.
R0: agents polydipsia mellitus regularly hyperglycaemia glucose polyuria polyphagia
base-103	60.54	0.88	Patients treated with antipsychotic drugs, including ZYPADHERA, should be monitored for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness). Patients with diabetes mellitus or with risk factors for development of diabetes should be monitored regularly for worsening glucose levels.
knn-103	43.05	0.75	Patients treated with antipsychotic medicines including ZYPADHERA should be monitored for symptoms of hyperglycemia (such as polydipsia, polyuria, polyphagia and weakness). Patients with diabetes mellitus or with risk factors for the development of diabetes should be monitored regularly for worsening glucose levels.

S-182	9 Erwachsene Die am häufigsten (≥ 1% der Patienten) berichteten Nebenwirkungen im Zusammenhang mit der Anwendung von Olanzapin in klinischen Prüfungen waren Schläfrigkeit, Gewichtszunahme, Eosinophilie, erhöhte Prolaktin-, Cholesterin-, Glukose- und Triglyceridspiegel (siehe Abschnitt 4.4), Glukosurie, Zunahme des Appetits, Schwindel, Akathisie, Parkinsonismus (siehe Abschnitt 4.4), Dyskinesie, orthostatische Hypotonie, anticholinerge Effekte, vorübergehende asymptomatische Erhöhungen von Lebertransaminasen (siehe Abschnitt 4.4), Ausschlag, Asthenie, Ermüdung und Ödeme.
T-182	Adults The most frequently (seen in ≥ 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic transaminases (see section 4.4), rash, asthenia, fatigue and oedema.
R0: triglyceride Adults eosinophilia glucosuria appetite parkinsonism orthostatic rash asthenia akathisia cholesterol fatigue
base-182	72.39	0.92	9 Adults The most commonly reported adverse events (≥ 1% of patients) related to olanzapine use in clinical trials were sleepiness, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increase in appetite, dizziness, acathia, parkinsonism (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of liver transaminases (see section 4.4), rash, asthenia, fatigue and oedema.
knn-182	58.93	0.83	9 Adults The most commonly reported adverse events (≥ 1% of patients) related to the use of olanzapine in clinical trials were drowsiness, weight gain, eosinophilia, elevated levels of prolactin, cholesterol, glucose and triglycerides (see Section 4.4), glucosuria, increase in appetite, dizziness, acathisia, parkinsonism (see Section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of liver transaminases (see Section 4.4), rash, asthenia, fatigue and edema.

S-193	Thrombozytopenie
T-193	Thrombocytopenia
R0: Thrombocytopenia
base-193	100.00	1.00	Thrombocytopenia
knn-193	0.00	0.00	thrombocytopenia

S-195	Erhöhte Cholesterinspiegel2,3 Erhöhte Glukosespiegel4 Erhöhte Triglyceridspiegel2,5 Glukosurie Zunahme des Appetits
T-195	Elevated cholesterol levels2,3 Elevated glucose levels4 Elevated triglyceride levels2,5 Glucosuria Increased appetite
R0: levels2,5 Increased Glucosuria levels2,3 Elevated levels4
base-195	0.00	0.50	Elevated cholesterol level2,3 Increased glucose level4 Increased triglyceride level2,5 Glucosuria increased appetite
knn-195	0.00	0.33	Increased cholesterol level2,3 Increased glucose level4 Increased triglyceride level2,5 Glucosuria Increase in appetite

S-221	3 Beobachtet wurden normale Nüchtern-Ausgangswerte (< 5,17mmol / l), die über die Normwerte anstiegen (≥ 6,2mmol / l).
T-221	3 Observed for fasting normal levels at baseline (< 5.17 mmol / l) which increased to high (≥ 6.2 mmol / l).
R0: Observed normal mmol
base-221	44.48	0.67	Smokers were observed to have normal fasting baseline values (< 5.17 mmol / l), which were higher than normal (≥ 6.2 mmol / l).
knn-221	16.81	0.33	3 Normal fasting baseline values (< 5.17mmol / l) were observed, which rose above the normal values (≥ 6.2mmol / l).

S-251	Gewichtszunahme9, erhöhte Triglyceridspiegel10, Zunahme des Appetits.
T-251	Weight gain9, elevated triglyceride levels10, increased appetite.
R0: gain9 levels10
base-251	65.80	0.50	Weight gain9, elevated triglyceride level10, increased appetite.
knn-251	0.00	0.00	Weight gain 9, increased triglyceride level10, increase in appetite.

S-257	Erhöhungen von Lebertransaminasen (ALT / AST; siehe Abschnitt 4.4).
T-257	Elevations of hepatic transaminases (ALT / AST; see section 4.4).
R0: Elevations
base-257	72.42	1.00	Elevations of hepatic transaminases (ALT / AST) (see section 4.4).
knn-257	75.77	0.00	Increases in liver transaminases (ALT / AST; see section 4.4).

S-259	Erniedrigtes Gesamtbilirubin, erhöhte GGT, erhöhte Plasmaprolaktinspiegel12.
T-259	Decreased total bilirubin, increased GGT, elevated plasma prolactin levels12.
R0: GGT Decreased levels12
base-259	63.40	0.67	Reduced total bilirubin, elevated GGT, elevated plasma prolactin levels12.
knn-259	48.33	0.33	Reduced total bilirubin, increased GGT, increased plasma prolactin level12.

S-280	5.1. Pharmakodynamische Eigenschaften
T-280	5.1 Pharmacodynamic properties
R0: Pharmacodynamic properties
base-280	0.00	1.00	5.1. Pharmacodynamic properties
knn-280	0.00	0.50	5.1. Pharmacodynamic Properties

S-283	In präklinischen Studien zeigte Olanzapin eine Reihe von Rezeptor-Affinitäten (Ki; < 100 nMol) auf Serotonin 5HT2A / 2C, 5HT3, 5HT6; Dopamin D1, D2, D3, D4, D5; cholinerge Muskarinrezeptoren (m1 - m5); α 1-adrenerge und Histamin H1-Rezeptoren.
T-283	In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki; < 100 nM) for serotonin 5-HT2A / 2C, 5-HT3, 5-HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors m1-m5; α -1 adrenergic; and histamine H1 receptors.
R0: D3 receptors 5-HT6 D5 m1-m5 -1 D1 histamine nM serotonin affinities D4 H1 D2 2C exhibited preclinical α muscarinic adrenergic cholinergic 5-HT2A 5-HT3
base-283	29.17	0.57	In preclinical trials, olanzapine demonstrated a number of receptor affinities (Kl; < 100 nmol) to serotinin 5HT2A / 2C, 5HT3, 5HT6, dopamine D1, D2, D3, D4, D5, cholinergic muscular receptor (m1 - m5), α 1 adrenergic and histamine H1 receptor.
knn-283	39.37	0.52	In preclinical studies olanzapine showed a number of receptor affinities (Ki; < 100 nMol) to serotonin 5HT2A / 2C, 5HT3, 5HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarine receptors (m1 - m5); α-adrenergic and histamine H1receptors.

S-305	Die Erfahrungen bei Jugendlichen (Alter 13-17 Jahre) sind begrenzt auf Kurzzeitdaten zur Wirksamkeit von oralem Olanzapin bei Schizophrenie (6 Wochen) und Manie assoziiert mit einer Bipolar-I-Erkrankung (3 Wochen).
T-305	The experience in adolescents (ages 13 to 17 years) is limited to short term oral olanzapine efficacy data in schizophrenia (6 weeks) and mania associated with bipolar I disorder (3 weeks), involving less than 200 adolescents.
R0: ages involving short
base-305	49.64	0.33	Experience with adolescents (aged 13-17 years) is limited to short term data on the efficacy of oral olanzapine in schizophrenia (6 weeks) and mania associated with bipolar I disease (3 weeks).
knn-305	46.24	0.00	Experience in adolescents (age 13-17 years) is limited to short-term data on the efficacy of oral olanzapine in schizophrenia (6 weeks) and mania associated with bipolar I disease (3 weeks).

S-323	Die Plasmaproteinbindung von Olanzapin im Konzentrationsbereich von etwa 7 bis 1.000 ng / ml beträgt ungefähr 93%.
T-323	The plasma protein binding of olanzapine is about 93% over the concentration range of 7 to about 1000 ng / mL.
R0: protein binding concentration
base-323	45.44	1.00	The plasma protein binding of olanzapine in the concentration range of 7 to 1,000 nl / ml is approximately 93%.
knn-323	21.87	0.67	The plasma protein integration of olanzapine in the concentration range of about 7 to 1,000 ng / ml is approximately 93%.

S-541	Zusätzlich muss ein aktualisierter RMP eingereicht werden • Wenn neue Informationen vorliegen, die einen Einfluss auf die derzeitigen Sicherheits- Spezifikationen, den Pharmakovigilanz-Plan oder die Risikominimierungsaktivitäten haben könnten • Innerhalb von 60 Tagen nach Erreichen eines wichtigen (Pharmakovigilanz- oder Risikominimierungs-) Meilensteins • Auf Anfrage durch die EMEA
T-541	In addition, an updated RMP should be submitted • When new information is received that may impact on the current Safety Specification, Pharmacovigilance Plan or risk minimisation activities • Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached • At the request of the EMEA
R0: minimisation current addition milestone Specification request reached
base-541	49.11	0.71	In addition, the updated RMP should be submitted • If new information is available which may affect the current safety specifications, pharmacovigilance plan or risk minimisation activities • Within 60 days following the achievement of an important (pharmacovigilance or risk minimisation) milestone • Upon request of the EMEA
knn-541	32.55	0.57	In addition, an updated RMP must be submitted • If there is new information that could affect current safety specifications, pharmacovigilance plan or risk mitigation activities • Within 60 days of reaching an important (pharmacovigilance or risk milestone) milestone • Upon request by EMEA

S-596	INHALT NACH GEWICHT, VOLUMEN ODER EINHEIT
T-596	CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
R0: UNIT WEIGHT VOLUME
base-596	0.00	0.67	CONTENTS TO WEIGHT, VOLUME OR UNITY
knn-596	0.00	0.33	CONTENT BALANCE, VOLUME OR UNITY

S-656	78 • Verwirrtheit • Reizbarkeit • Aggression • Schwierigkeiten beim Sprechen • Schwierigkeiten beim Gehen • Krampfanfälle • Schwindel • Orientierungsstörungen • Angst • Blutdruckanstieg • Schwäche • Muskelsteifheit oder Zittern
T-656	aggression • difficulty talking • difficulty walking • convulsions
R0: walking talking difficulty
base-656	8.93	0.67	78 • confusion • irritability • aggression • dysarthria • dysarthria • difficulty walking • convulsion • dizziness • disorientation • anxiety • hypertension • weakness • muscle rigidity or tremor
knn-656	0.00	0.33	78 • Confusion • Irritability • Aggression • Difficulty speaking • Difficulty walking • Seizures • Dizziness • Disorientation • Anxiety • Blood pressure increase • Weakness • Muscle stiffness or tremor

S-705	Sie dürfen das Arzneimittel nach dem auf dem ZYPADHERA Umkarton angegebenen Verfalldatum nicht mehr anwenden.
T-705	The injection must not be given after the expiry date which is stated on the ZYPADHERA carton.
R0: stated expiry
base-705	0.00	0.50	You should not use the product after the expiry of the ZYPADHERA packaging.
knn-705	0.00	0.00	You may no longer use the medicine after the expiration date indicated on the ZYPADHERA packaging.

S-38	Anwendung bei älteren Patienten (> 65 Jahre):
T-38	Use in elderly patients (> 65 years):
R0: elderly &gt;
base-38	89.32	1.00	2 Use in elderly patients (> 65 years):
knn-38	70.71	0.50	Use in older patients (> 65 years):

S-42	Eine Anpassung der Dosierung ist nicht erforderlich (siehe Abschnitt 5.2).
T-42	No dosage adjustment is required (see section 5.2).
R0: adjustment required
base-42	63.16	1.00	Dosage adjustment is not required (see section 5.2).
knn-42	38.72	0.50	An adjustment of the dosage is not necessary (see section 5.2).

S-100	Bei mit Rapamune behandelten Patienten wurde über eine Flüssigkeitsansammlung, einschließlich periphere Ödeme, Lymphödeme, Pleuraerguss und Perikardergüsse (inklusive hämodynamisch relevanter Ergüsse bei Kindern und Erwachsenen), berichtet.
T-100	There have also been reports of fluid accumulation, including peripheral oedema, lymphoedema, pleural effusion, and pericardial effusions (including haemodynamically significant effusions in children and adults), in patients receiving Rapamune.
R0: oedema pericardial accumulation haemodynamically effusion pleural effusions fluid peripheral lymphoedema
base-100	55.35	0.70	Fluid retention in patients receiving Rapamune, including peripheral oedema, lymphedema, pleural effusion, and pericardial effusions (including haemodynamically relevant effusions in children and adults), was reported.
knn-100	36.41	0.60	Fluid retention was reported in patients treated with Rapamune, including peripheral oedema, lymphedema, pleural effusion and pericardial effusions (including hemodynamically relevant effusions in children and adults).

S-128	Sirolimus wird in beträchtlichem Umfang durch das CYP3A4-Isoenzym in der Darmwand und der Leber metabolisiert.
T-128	Sirolimus is extensively metabolised by the CYP3A4 isozyme in the intestinal wall and liver.
R0: metabolised intestinal isozyme wall
base-128	61.05	0.75	Sirolimus is significantly metabolised by the CYP3A4 isoenzyme in the intestinal wall and liver.
knn-128	53.04	0.50	Sirolimus is significantly metabolized by the CYP3A4 isoenzyme in the intestinal wall and liver.

S-132	CYP3A4-Induktoren (wie Rifampicin oder Rifabutin) erhöhen den Sirolimus-Metabolismus und senken die Sirolimus-Spiegel.
T-132	Inducers of CYP3A4 (such as rifampin or rifabutin) increase the metabolism of sirolimus and decrease sirolimus levels.
R0: Inducers
base-132	100.00	1.00	Inducers of CYP3A4 (such as rifampin or rifabutin) increase the metabolism of sirolimus and decrease sirolimus levels.
knn-132	31.97	0.00	CYP3A4 inductors (such as rifampicin or rifabutin) increase the sirolimus metabolism and lower the sirolimus levels.

S-158	Die Vollblut-Sirolimus-Cmax, -tmax und -AUC waren um das 2,3fache, 1,1fache bzw. 2,2fache erhöht.
T-158	Whole blood sirolimus Cmax, tmax, and AUC were increased 2.3-fold, 1.1-fold, and 2.2-fold, respectively.
R0: 2.2-fold 2.3-fold 1.1-fold
base-158	82.62	0.67	Whole blood sirolimus Cmax, tmax, and AUC were increased 1.4-fold, 2.3-fold, and 2.2-fold, respectively.
knn-158	35.92	0.00	Whole blood sirolimus Cmax, tmax and AUC were increased by 2.3 times, 1.1 times and 2.2 times, respectively.

S-163	Die Vollblut-Sirolimus-Cmax, -tmax und -AUC waren um das 4,4-, 1,4- bzw. 4,2fache erhöht.
T-163	Whole blood sirolimus Cmax, tmax, and AUC were increased 4.4-fold, 1.4-fold, and 4.2-fold, respectively.
R0: 4.2-fold
base-163	100.00	1.00	Whole blood sirolimus Cmax, tmax, and AUC were increased 4.4-fold, 1.4-fold, and 4.2-fold, respectively.
knn-163	26.83	0.00	The thoroughbred sirolimus Cmax, tmax and AUC were increased 4.4, 1.4 and 4.2 times respectively.

S-212	Stoffwechsel- und Ernährungs- störungen
T-212	Metabolism and Hypokalaemia nutrition disorders
R0: Hypokalaemia nutrition Metabolism
base-212	0.00	0.67	Metabolism and nutrition disorders
knn-212	0.00	0.00	Metabolic and nutritional disorders

S-213	Hypokaliämie Hypophosphatämie Hypercholesterinämie Hyperglykämie Hypertriglyceridämie
T-213	Hypophosphataemia Hypercholesterolaemia Hyperglycaemia Hypertriglyceridaemia
R0: Hyperglycaemia Hypophosphataemia Hypercholesterolaemia Hypertriglyceridaemia
base-213	66.87	1.00	Hypokalaemia Hypophosphataemia Hypercholesterolaemia Hyperglycaemia Hypertriglyceridaemia
knn-213	0.00	0.00	Hypokalemia Hypophosphatemia Hypercholesterolemia Hyperglycemia Hypertriglyceridemia

S-281	Sirolimus hemmt eine durch die meisten Stimuli ausgelöste T-Zell-Aktivierung, indem es die calciumabhängige und die calciumunabhängige intrazelluläre Signaltransduktion blockiert.
T-281	Sirolimus inhibits T cell activation induced by most stimuli, by blocking calcium dependent and calcium independent intracellular signal transduction.
R0: transduction cell dependent independent signal blocking activation stimuli intracellular induced
base-281	33.71	0.70	Sirolimus inhibits T-cell activation induced by most stimuli by blocking calcium-dependent and calcium-independent intracellular signal transduction.
knn-281	20.78	0.60	Sirolimus inhibits T-cell activation triggered by most stimuli by blocking calcium-dependent and calcium-independent intracellular signal transduction.

S-338	Bei gesunden Probanden veränderte eine fettreiche Mahlzeit die Bioverfügbarkeitscharakteristika von Sirolimus in flüssiger Form zum Einnehmen.
T-338	In healthy volunteers, a high fat meal altered the bioavailability characteristics of oral liquid sirolimus.
R0: altered characteristics liquid fat meal
base-338	73.23	1.00	In healthy volunteers, a high fat meal altered the bioavailability characteristics of sirolimus in liquid form.
knn-338	37.18	0.80	In healthy subjects, a high-fat meal altered the bioavailability characteristics of sirolimus in liquid form.

S-356	Nebenwirkungen, die nicht in klinischen Studien beobachtet wurden, aber bei Tieren nach Exposition im humantherapeutischen Bereich auftraten und als möglicherweise relevant für die klinische Anwendung zu bewerten sind, waren wie folgt: Pankreas-Inselzellvakuolisierung, testikuläre Tubulusdegeneration, gastrointestinale Ulzeration, Knochenfrakturen und Callus, hepatische Hämatopoese und pulmonale Phospholipidose.
T-356	Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows: pancreatic islet cell vacuolation, testicular tubular degeneration, gastrointestinal ulceration, bone fractures and calluses, hepatic haematopoiesis, and pulmonary phospholipidosis.
R0: degeneration pancreatic calluses haematopoiesis bone islet fractures phospholipidosis vacuolation ulceration testicular relevance tubular
base-356	47.03	0.77	Adverse reactions that were not observed in clinical trials but occurred in animals after exposure to human therapy and may be relevant for clinical use are as follows: pancreatic islet cell vacuolization, testicular tubular degeneration, gastrointestinal ulceration, bone fractures and callus, hepatic haematopoiesis, and pulmonary phospholipidosis.
knn-356	45.69	0.69	Side effects that were not observed in clinical studies but occurred in animals after exposure to human therapy and may be relevant for clinical use were as follows: pancreatic islet cell vacuolization, testicular tubular degeneration, gastrointestinal ulceration, bone fractures and callus, hepatic hematopoiesis and pulmonary phospholipidosis.

S-382	Im Kühlschrank bei 2 ° C - 8 ° C lagern.
T-382	Store in a refrigerator at 2 C - 8 C.
R0: C. Store refrigerator
base-382	46.60	1.00	Store in the refrigerator at 2 ° C - 8 C.
knn-382	0.00	0.67	Store in the fridge at 2 ° C - 8 ° C.

S-441	Bei Patienten mit Saccharase-Isomaltase- Mangel, Fructose-Intoleranz, Glukose-Galaktose-Absorptionsstörungen, Galaktose-Intoleranz (z.B. Galaktosämie) oder Lapp-Laktase-Mangel sollte vor der Verordnung von Sirolimus-Tabletten eine sorgfältige Nutzen-Risiko-Bewertung vorgenommen werden.
T-441	In those patients with a history of sucrase insufficiency, isomaltase insufficiency, fructose intolerance, glucose malabsorption, galactose malabsorption, galactose intolerance (e. g., galactosemia), or Lapp lactase deficiency, a careful risk / benefit assessment should be performed prior to prescribing sirolimus tablets.
R0: lactase insufficiency isomaltase careful fructose assessment Lapp deficiency intolerance malabsorption glucose galactosemia sucrase galactose prescribing
base-441	46.68	0.73	In patients with sucrose isomaltase deficiency, fructose intolerance, glucose galactose absorption abnormalities, galactose intolerance (e. g. galactosemia) or flap lactase deficiency, a careful risk / benefit assessment should be performed before prescribing sirolimus tablets.
knn-441	26.01	0.60	Patients with sucrose isomaltase deficiency, fructose intolerance, glucose galactose absorption disorders, galactose intolerance (e.g. galactosemia) or flap lactase deficiency should be carefully assessed before prescribing sirolimus tablets.

S-496	Macrogol Glycerolmonooleat Pharmazeutische Glasur Calciumsulfat wasserfrei Mikrokristalline Cellulose Sucrose Titandioxid (E 171) Poloxamer 188 α -Tocopherol Povidon Carnaubawachs Rote Drucktinte S-1-15095 (Schellack Glasur ca.
T-496	Macrogol Glyceryl monooleate Pharmaceutical glaze Anhydrous calcium sulphate Microcrystalline cellulose Sucrose Titanium dioxide Poloxamer 188 -tocopherol Povidone Carnauba wax:
R0: dioxide Titanium wax Sucrose Carnauba monooleate Poloxamer Microcrystalline cellulose Povidone sulphate Anhydrous glaze Pharmaceutical Glyceryl -tocopherol
base-496	0.00	0.56	Macrogol glycerin monooleate Pharmaceutic glaze Calcium sulfate anhydrous Microcrystalline Cellulose Sucrose Titanium Dioxide (E 171) Poloxamer 188 α -Tocopherol Povidone Carnauba wax
knn-496	0.00	0.44	Macrogol Glycerol Monooleate Pharmaceutical Glaze Calcium Sulfate anhydrous Microcrystalline Cellulose Sucrose Titanium Dioxide (E 171) Poloxamer 188 α -Tocopherol Povidone Carnauba Wax Red Printing Ink S-1-15095 (Shellac Glaze approx.

S-538	Wyeth Medica Ireland Little Connell Newbridge, Co.
T-538	Wyeth Medica Ireland Little Connell Newbridge, Co.
R0: Medica Ireland Newbridge Connell
base-538	100.00	1.00	Wyeth Medica Ireland Little Connell Newbridge, Co.
knn-538	75.06	0.75	Wyeth Medical Ireland Little Connell Newbridge, Co.

S-554	1 ANGABEN AUF DER ÄUSSEREN UMHÜLLUNG UND AUF DEM BEHÄLTNIS ANGABEN AUF DEM ÄUSSEREN 60 ml UMKARTON (ENTHÄLT DIE SPRITZEN UND FLASCHE IM UMKARTON)
T-554	53 PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING TEXT FOR 60 ml OUTER CARTON (CONTAINING SYRINGES / BOTTLE IN CARTON)
R0: SYRINGES BOTTLE CARTON OUTER PACKAGING
base-554	0.00	0.40	1 PARTICULARS ON THE OUTER PACKAGE AND ON THE PACKAGE OF THE OUTER 60 mL OVERPACKAGE (CONTAINS THE SYRINGS AND BOTTLE IN THE PACKAGE)
knn-554	0.00	0.20	1 INFORMATION ON THE EXTERNAL WAVE AND ON THE CONTAINMENT INFORMATION ON THE EXTERNAL 60 ml OVERBOARD (INCLUDES THE SYRINGS AND BOTTLE IN THE EXTERNAL CARD)

S-626	13 B.
T-626	65 B.
R0: B.
base-626	0.00	1.00	13 B.
knn-626	0.00	0.00	13 B

S-710	Bringen Sie immer die etikettierte Arzneimittel- flasche mit, auch wenn diese leer ist.
T-710	Always take the labelled medicine bottle with you, even if it is empty.
R0: labelled
base-710	79.17	1.00	Always carry your labelled medicine bottle with you, even if it is empty.
knn-710	46.93	0.00	Always bring the labeled medicine bottle, even if it is empty.

S-729	Wundheilungsstörungen (dies kann das Auseinanderweichen der verschiedenen Schichten einer chirurgischen Wunde oder das Klaffen der Wundnaht beinhalten), Schwellungen, Infektionen (einschließlich lebensbedrohlicher Infektionen)
T-729	Fluid collection around the kidney, swelling of the extremities, fever, pain Impaired healing (this may include separation of the layers of a surgical wound or suture line), swelling, infections (including life-threatening infections)
R0: surgical fever life-threatening separation collection suture layers extremities Fluid swelling
base-729	35.62	0.60	Impaired wound healing (this may be the separation of the different layers of a surgical wound or the gaping of the wound suture), swelling, infection (including life-threatening infections)
knn-729	31.03	0.50	Wound healing disorders (this may involve the disintegration of the different layers of a surgical wound or the gaping of the suture), swelling, infection (including life-threatening infections)

S-734	Schneller Herzschlag Flüssigkeitsansammlung im Herzbeutel, die in einigen Fällen die Pumpfunktion des Herzens vermindern kann
T-734	Rapid heart rate Fluid collection in the sac around the heart that, in some cases, may decrease the heart's ability to pump blood
R0: sac Rapid
base-734	0.00	1.00	Rapid heartbeat fluid accumulation in the pericardial sac, which may in some cases decrease your heart "s pumping function
knn-734	0.00	0.50	Rapid heartbeat fluid build-up in the pericardium, which in some cases can decrease the pumping function of the heart

S-736	Erhöhter Blutdruck Blutgerinnsel in den Beinvenen Blutgerinnsel in der Lunge
T-736	Increased blood pressure Blood clots in the legs Blood clots in the lung
R0: clots legs
base-736	0.00	0.50	Aspartate blood clots in the leg vascular blood clots in the lungs
knn-736	0.00	0.00	Increased blood pressure Clots in the leg veins Clots in the lungs

S-789	Tél / Tel: + 32 10 49 47 11 Fax: + 32 10 49 48 70
T-789	Tél / Tel: + 32 10 49 47 11 Fax: + 32 10 49 48 70
R0: Tel Tél Fax
base-789	100.00	1.00	Tél / Tel: + 32 10 49 47 11 Fax: + 32 10 49 48 70
knn-789	82.13	0.33	Telephone: + 32 10 49 47 11 Fax: + 32 10 49 48 70

S-31	Während der Behandlung einer Schizophrenie, einer manischen Episode und zur Phasenprophylaxe bei bipolaren Störungen kann die Dosis anschließend innerhalb eines Bereichs von 5-20 mg / Tag auf der Grundlage des individuellen klinischen Zustands angepaßt werden.
T-31	During treatment for schizophrenia, manic episode and recurrence prevention in bipolar disorder, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5- 20 mg / day.
R0: range 5- subsequently basis dosage status adjusted individual
base-31	35.95	0.50	During the treatment of schizophrenia, manic episode and the prevention of recurrence in bipolar disorder, the dose can be adjusted within a range of 5-20 mg / day on the basis of the individual clinical condition.
knn-31	30.39	0.38	During the treatment of schizophrenia, manic episode and phase prophylaxis of bipolar disorder, the dose can then be adjusted within a range of 5-20 mg / day based on the individual clinical condition.

S-39	In Fällen von mittelgradiger Leberinsuffizienz (Zirrrhose, Child-Pugh Klasse A oder B) sollte die Anfangsdosis 5 mg betragen und nur mit Vorsicht erhöht werden.
T-39	In cases of moderate hepatic insufficiency (cirrhosis, Child-Pugh Class A or B), the starting dose should be 5 mg and only increased with caution.
R0: Class increased insufficiency Child-Pugh caution cirrhosis
base-39	34.72	0.67	In patients with moderate hepatic impairment (cirrhosis, Child- Pugh Class A or B) the starting dose is 5 mg and should be increased with caution.
knn-39	46.16	0.50	In cases of moderate liver failure (cirrhosis, Child- Pugh class A or B) the starting dose should be 5 mg and should be increased only with caution.

S-129	Es liegen keine hinreichenden und kontrollierten Studien bei schwangeren Frauen vor.
T-129	There are no adequate and well-controlled studies in pregnant women.
R0: well-controlled pregnant women adequate
base-129	70.17	0.75	There are no adequate and controlled studies in pregnant women.
knn-129	48.33	0.50	There are no sufficient and controlled studies in pregnant women.

S-132	Sehr selten gab es Spontanberichte über Zittern, Hypertonie, Lethargie und Schläfrigkeit bei Kindern deren Mütter während des 3. Trimenon der Schwangerschaft Olanzapin angewendet hatten.
T-132	Spontaneous reports have been very rarely received on tremor, hypertonia, lethargy and sleepiness, in infants born to mothers who had used olanzapine during the 3rd trimester.
R0: born sleepiness trimester infants mothers reports 3rd hypertonia lethargy Spontaneous
base-132	20.13	0.60	Spontaneous reports of tremor, hypertension, lethargy, and insomnia were reported very rarely in children whose mothers have been using olanzapine during the 3rd trimester of pregnancy.
knn-132	26.18	0.50	Very rarely were there spontaneous reports of tremors, hypertension, lethargy and drowsiness in children whose mothers had used olanzapine during the 3rd trimester of pregnancy.

S-140	Erwachsene Die am häufigsten (≥ 1% der Patienten) berichteten Nebenwirkungen im Zusammenhang mit der Anwendung von Olanzapin in klinischen Prüfungen waren Schläfrigkeit, Gewichtszunahme, Eosinophilie, erhöhte Prolaktin-, Cholesterin-, Glukose- und Triglyceridspiegel (siehe Abschnitt 4.4), Glukosurie, Zunahme des Appetits, Schwindel, Akathisie, Parkinsonismus (siehe Abschnitt 4.4), Dyskinesie, orthostatische Hypotonie, anticholinerge Effekte, vorübergehende asymptomatische Erhöhungen von Lebertransaminasen (siehe Abschnitt 4.4), Ausschlag, Asthenie, Ermüdung und Ödeme.
T-140	Adults The most frequently (seen in ≥ 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic transaminases (see section 4.4), rash, asthenia, fatigue and oedema.
R0: oedema triglyceride eosinophilia glucosuria appetite parkinsonism orthostatic rash asthenia akathisia cholesterol fatigue
base-140	76.52	0.83	Adults The most commonly reported adverse reactions associated with the use of olanzapine in clinical trials (≥ 1% of patients) were sleepiness, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increase in appetite, dizziness, acathisia, parkinsonism (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient, asymptomatic elevations of liver transaminases (see section 4.4), rash, asthenia, fatigue and edema.
knn-140	60.92	0.75	Adults The most commonly reported adverse events associated with the use of olanzapine in clinical trials (≥ 1% of patients) were drowsiness, weight gain, eosinophilia, elevated levels of prolactin, cholesterol, glucose and triglycerides (see Section 4.4), glucosuria, increase in appetite, dizziness, acathisia, parkinsonism (see Section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of liver transaminases (see Section 4.4), rash, asthenia, fatigue and edema.

S-151	Thrombozytopenie
T-151	Thrombocytopenia
R0: Thrombocytopenia
base-151	100.00	1.00	Thrombocytopenia
knn-151	0.00	0.00	thrombocytopenia

S-152	Erkrankungen des Immunsytems Allergische Reaktion Stoffwechsel- und Ernährungsstörungen Gewichtszunahme1
T-152	Immune system disorders Allergic reaction Metabolism and nutrition disorders Weight gain1
R0: nutrition Allergic reaction Metabolism Immune Weight gain1
base-152	35.56	0.57	Blood and immune system disorders Allergic reaction Metabolic and nutrition disorders Weight gain 1
knn-152	0.00	0.43	Diseases of the immune system Allergic reaction Metabolic and nutritional disorders Weight gain 1

S-153	Erhöhte Cholesterinspiegel2,3 Erhöhte Glukosespiegel4 Erhöhte Triglyceridspiegel2,5 Glukosurie Zunahme des Appetits
T-153	Elevated cholesterol levels2,3 Elevated glucose levels4 Elevated triglyceride levels2,5 Glucosuria Increased appetite
R0: levels2,5 Increased Glucosuria levels2,3 Elevated levels4
base-153	0.00	0.50	Elevated cholesterol level2,3 Increased glucose level4 Increased triglyceride level2,5 Glucosuria increased appetite
knn-153	0.00	0.33	Increased cholesterol level2,3 Increased glucose level4 Increased triglyceride level2,5 Glucosuria Increase in appetite

S-173	Hohe Kreatin- Phosphokinase Werte Erhöhtes Gesamtbilirubin
T-173	High creatine phosphokinase Increased total bilirubin
R0: creatine total bilirubin
base-173	0.00	0.67	High creatinine phosphokinase levels Elevated total bilirubin
knn-173	0.00	0.33	High Creatine Phosphokinase Values Increased Total bilirubin

S-179	9 3 Beobachtet wurden normale Nüchtern-Ausgangswerte (< 5,17mmol / l), die über die Normwerte anstiegen (≥ 6,2mmol / l).
T-179	8 3 Observed for fasting normal levels at baseline (< 5.17 mmol / l) which increased to high (≥ 6.2 mmol / l).
R0: Observed normal mmol
base-179	42.97	0.67	9 3 Normal fasting baseline values (< 5.17 mmol / l) were observed, which were higher than the normal values (≥ 6.2 mmol / l).
knn-179	16.17	0.33	9 3 Normal fasting baseline values (< 5.17mmol / l) were observed, which rose above the normal values (≥ 6.2mmol / l).

S-180	Veränderungen grenzwertiger Ausgangs-Nüchtern-Gesamtcholesterin-Werte (≥ 5,17- < 6,2mmol / l) zu hohen Werten (≥ 6,2mmol / l) waren sehr häufig.
T-180	Changes in total fasting cholesterol levels from borderline at baseline (≥ 5.17 - < 6.2 mmol) to high (≥ 6.2 mmol) were very common.
R0: borderline
base-180	43.89	1.00	Changes in borderline baseline fasting total cholesterol values (≥ 5.17 - < 6.2 mmol / l) to high values (≥ 6.2 mmol / l) were very common.
knn-180	33.40	0.00	Changes in baseline fasting total cholesterol (≥ 5.17- < 6.2mmol / l) to high values (≥ 6.2mmol / l) were very common.

S-210	Gewichtszunahme9, erhöhte Triglyceridspiegel10, Zunahme des Appetits.
T-210	Weight gain9, elevated triglyceride levels10, increased appetite.
R0: gain9 levels10
base-210	65.80	0.50	Weight gain9, elevated triglyceride level10, increased appetite.
knn-210	0.00	0.00	Weight gain 9, increased triglyceride level10, increase in appetite.

S-232	Standardverfahren zur Behandlung einer Überdosis können angezeigt sein (d.h. Magenspülung, Gabe von Aktivkohle).
T-232	Standard procedures for management of overdose may be indicated (i. e. gastric lavage, administration of activated charcoal).
R0: activated management i. Standard gastric procedures lavage
base-232	71.87	0.71	Standard procedures for the treatment of overdose may be indicated (i. e. gastric flushing, administration of activated charcoal).
knn-232	54.30	0.57	Standard procedures for the treatment of an overdose may be indicated (i.e. gastric irrigation, administration of activated carbon).

S-244	In präklinischen Studien zeigte Olanzapin eine Reihe von Rezeptor-Affinitäten (Ki; < 100 nMol) auf Serotonin 5HT2A / 2C, 5HT3, 5HT6 Dopamin D1, D2, D3, D4, D5; cholinerge Muskarinrezeptoren (m1 - m5); α 1 adrenerge und Histamin H1-Rezeptoren.
T-244	In preclinical studies, olanzapine exhibited a range of receptor affinities (Ki; < 100 nM) for serotonin 5 HT2A / 2C, 5 HT3, 5 HT6; dopamine D1, D2, D3, D4, D5; cholinergic muscarinic receptors m1-m5; α 1 adrenergic; and histamine H1 receptors.
R0: D3 receptors D5 m1-m5 D1 histamine nM HT2A HT6 serotonin affinities D4 H1 D2 2C exhibited preclinical α HT3 muscarinic adrenergic cholinergic
base-244	36.82	0.73	In preclinical trials olanzapine showed various receptor affiniations (Kl; < 100 mmol) on serotonin 5HT2A / 2C, 5 HT3, 5 HT6 dopamine D1, D2, D3, D4, D5, cholinergic muscarine receptors (m1 to m5), α 1 adrenergic and histamine H1 receptor.
knn-244	48.32	0.68	In preclinical studies olanzapine showed a number of receptor affinities (Ki; < 100 nMol) to serotonin 5HT2A / 2C, 5HT3, 5HT6 dopamine D1, D2, D3, D4, D5; cholinergic muscarine receptors (m1 - m5); α 1 adrenergic and histamine H1 receptors.

S-252	In zwei von zwei placebokontrollierten Studien und zwei von drei Studien mit wirksamer Vergleichssubstanz bei insgesamt über 2900 schizophrenen Patienten, die sowohl positive als auch negative Symptome aufwiesen, war Olanzapin mit einer statistisch signifikant größeren Besserung der negativen sowie auch der positiven Symptome verbunden.
T-252	In two of two placebo and two of three comparator controlled trials with over 2,900 schizophrenic patients presenting with both positive and negative symptoms, olanzapine was associated with statistically significantly greater improvements in negative as well as positive symptoms.
R0: improvements 2,900 negative positive
base-252	24.78	0.75	Olanzapine was associated with a statistically significant improvement in both positive and negative symptoms in two of two placebo- controlled clinical trials and two of three trials with an effective antidepressant in a total of more than 2,900 schizophrenic patients with both positive and negative symptoms.
knn-252	28.76	0.50	In two out of two placebo-controlled studies and two out of three studies with an effective comparison substance in a total of over 2900 schizophrenic patients who exhibited both positive and negative symptoms, olanzapine was associated with a statistically significantly greater improvement in both negative and positive symptoms.

S-269	Die absolute orale Bioverfügbarkeit im Vergleich zu einer i.v.-Applikation wurde nicht untersucht.
T-269	Absolute oral bioavailability relative to intravenous administration has not been determined
R0: Absolute intravenous determined
base-269	0.00	0.33	Absolute oral bioavailability compared to an IV application has not been studied.
knn-269	0.00	0.00	The absolute oral bioavailability in comparison to an i.v. application was not investigated.

S-287	Die Plasmaproteinbindung von Olanzapin betrug etwa 93% über einen Konzentrationsbereich von etwa 7 bis etwa 1.000 ng / ml.
T-287	The plasma protein binding of olanzapine was about 93% over the concentration range of about 7 to about 1000 ng / ml.
R0: protein binding concentration
base-287	49.35	1.00	The plasma protein binding of olanzapine was approximately 93% over a concentration range of 7 to about 1,000 ng / ml.
knn-287	63.62	0.67	The plasma protein integration of olanzapine was about 93% over a concentration range of about 7 to about 1,000 ng / ml.

S-582	Nicht über 25ºC lagern.
T-582	Do not store above 25º C.
R0: C. store 25º
base-582	41.11	0.67	Do not store above 25 ° C.
knn-582	45.48	0.33	Do not store above 25ºC.

S-736	INHALT NACH GEWICHT, VOLUMEN ODER EINHEITEN
T-736	CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
R0: UNIT WEIGHT VOLUME
base-736	0.00	0.67	CONTENTS TO WEIGHT, VOLUME OR UNITS
knn-736	0.00	0.33	CONTENT BALANCE, VOLUME OR UNITIES

S-847	(Tablettenfilm) Macrogol und Eisen (III) -oxid (E 172)
T-847	(tablet coating) macrogol and synthetic red iron oxide (E172)
R0: E172
base-847	100.00	1.00	(tablet coating) macrogol and synthetic red iron oxide (E172)
knn-847	0.00	0.00	Macrogol and Iron (III) Oxide (E 172)

S-868	Norge Eli Lilly Norge A.S Tlf: + 47 22 88 18 00 Österreich Eli Lilly Ges. m.b.H.
T-868	Nederland Eli Lilly Nederland B.V. Tel: + 31 (0) 30 6025800 Norge Eli Lilly Norge A.S Tlf: + 47 22 88 18 00 Österreich Eli Lilly Ges. m.b.H.
R0: B.V. Norge m.b.H. Ges. Österreich A.S
base-868	41.47	0.67	Norge Eli Lilly Norge A.S Tlf: + 47 22 8 18 00 Austria Eli Lilly Ges. m.b.H.
knn-868	22.87	0.33	Norge Eli Lilly Norge A.S Tlf: + 47 22 88 18 00 Austria Eli Lilly GmbH

